Across TCGA pan-cancer cohorts, RPL10P17 RNA differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of RPL10P17’s most consistent transcriptional readouts.

The strongest signal is observed in prostate adenocarcinoma (PRAD), where RPL10P17 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RPL10P17 is over-expressed in tumor, although a few such as BRCA show the opposite, repressed pattern.

PRAD, KIRC, and BRCA are the cancer types where RPL10P17 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPL10P17 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PRAD	All	All	+0.093	.002	2	view →
KIRC	All	All	+0.038	.025	2	view →
BRCA	Female	All	−0.049	.045	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: RPL10P17 RNA expression & survival · all RPL10P17 data types